From family history to preventive action: How genetic testing empowered a mother-daughter journey with breast cancer risk

Jen Black’s journey with genetic testing for hereditary cancer started with an itch. It wasn’t a literal impulse to scratch; it was an urge to be proactive about her health due to her family history of cancer.

Ethisphere Recognizes Labcorp with Compliance Leader Verification™

Phoenix, AZ, October 8, 2024 – Ethisphere, a global leader in defining and advancing the standards of ethical business practices, announced today that Labcorp earned the coveted Compliance Leader Verification from August 2024 through December 2025.

Leveraging telehealth to serve underrepresented populations: Bridging gaps and promoting health equity

Learn how telehealth has immense potential as a critical tool for expanding access to healthcare, especially for underrepresented populations facing health disparities. By leveraging telehealth services grounded in principles of value-based care and population health management, we can bridge gaps in care and make definitive progress toward health equity.

Accelerating CAR T-cell therapy clinical trial timelines with comprehensive biomarker-driven strategies

Chimeric antigen receptor (CAR) T-cell therapy is one of the fastest-growing sectors within oncology therapeutic development. This advanced form of immunotherapy can deliver “designer” T-cells to specifically recognize, and attack, cancer based on unique tumor-associated antigens, offering a highly targeted and personalized approach. Recently, adoptive cell therapy (ACT) has received considerable attention due to the success of CAR T-cell therapy in treating hematological malignancies. This article focuses on CAR T-cell therapies in cancer and discusses how biopharmaceutical companies can leverage a comprehensive biomarker strategy for their drug development programs to accelerate clinical trial timelines and better predict clinical outcomes.

Six FDA recommendations on NAMs

Three ways to strengthen the immune system

What if instead of referring to the next few months as flu season, we reframed our perspective and referred to this time as immune system empowerment season? While it doesn’t necessarily roll off the tongue, it certainly represents a more proactive and action-oriented approach in fighting off many of the illnesses associated with fall weather. 

Kathryn E. Wengel

Kathryn E. Wengel has served as a director of the Company since March 25, 2021.

Paul B. Rothman, M. D.

Paul B. Rothman has served as a director of the Company and member of the Quality and Compliance Committee since June 6, 2023.

Richelle P. Parham

Richelle Parham has served as a director of the Company since February 8, 2016 and Chairperson of the Compensation and Human Capital Committee since June 2023.

Peter M. Neupert

Peter M. Neupert has served as a director of the Company since January 1, 2013.